Effects of vitamin D2 supplementation on insulin sensitivity and metabolic parameters inmetabolic syndrome patients

Journal of Endocrinological Investigation

Volumn 36, Issue 8, 2013, Pages 558-563

  Wongwiwatthananukit, S ^a   Sansanayudh, N ^b   Phetkrajaysang, N ^c   Krittiyanunt, S ^c  

^a UNIVERSITY OF HAWAII AT HILO   (United States)

^b PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Insulin sensitivity; Metabolic parameters; Metabolic syndrome; Vitamin D2

Indexed keywords

25 HYDROXYVITAMIN D; CALCIFEROL BD; ERGOCALCIFEROL; INSULIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG SAFETY; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ADULT; AGED; AGED, 80 AND OVER; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; ERGOCALCIFEROLS; FEMALE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MODELS, BIOLOGICAL; PLACEBOS; VITAMIN D;

EID: 84885620757     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8817     Document Type: Article

References (33)

1. Holick MF. Vitamin D deficiency. N Engl J Med 2007, 357: 266-81.
2. Martini LA, Wood RJ. Vitamin D status and the metabolic syndrome. Nutr Rev 2006, 64: 479-86.
3. Kim MK, Kang MI, Oh KW, et al. The association of serum vitamin D level with presence of metabolic syndrome and hypertension in middle-aged Korean subjects. Clin Endocrinol 2010, 73: 330-8.
4. Soontrapa S, Soontrapa S, Chailurkit L. The prevalence and the calcidiol levels of vitamin D deficiency in the elderly Thai women in municipality of Khon Kaen province, Thailand. Srinagarind Med J 2002, 17: 231-8.
5. Athisakul S, Songmuang SB, Buddhari W. Prevalence of hypovitaminosis D in heart failure patients at King Chulalongkorn Memorial hospital. Thai Heart J 2010, 23: 154-63.
6. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120: 1640-5.
7. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004, 79: 820-5.
8. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among US adults. Diabetes Care 2005, 28: 1228-30.
9. Reis JP, Von Muhlen D, Miller ER. Relation of 25-hydroxyvitamin D and parathyroid hormone levels with metabolic syndrome among US adults. Eur J Endocrinol 2008, 159: 41-8.
10. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxyvitamin D is predictive of future glycemic status and insulin resistance: the medical research council prospective study 1990-2000. Diabetes 2008, 57: 2619-25.
11. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement executive summary. Circulation 2005, 112: 2735-52.
12. Montgomery DC. Design and analysis of experiments. 6th ed. Hoboken, NJ: John Wiley & Sons, Inc., 2005.
13. Jorde R, Sneve M, Torjesen P, Figenschau Y. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med 2010, 267: 462-72.
14. Bland R, Markovic D, Hills CE, et al. Expression of 25-hydroxyvitamin D3-1 alpha hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol 2004, 89-90: 121-5.
15. Maestro B, Campion J, Davila N, Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cell. Endocr J 2000, 47: 383-91.
16. Jorde R, Figenschau Y. Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur J Nutr 2009, 48: 349-54.
17. Nagpal J, Pande JN, Bhartia A. A double-blind, randomized, placebo- controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med 2009, 26: 19-27.
18. Von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomized, placebo-controlled trial. Br J Nutr 2010, 103: 549-55.
19. Vilarrasa N, Vendrell J, Maravall J, et al. Is plasma 25(OH)D related to adipokines, inflammatory cytokines and insulin resistance in both a healthy and morbidly obese population? Endocrine 2010, 38: 235-42.
20. Rueda S, Fernandez C, Romero F, Osaba JM, Vidal J. Vitamin D, PTH and the metabolic syndrome in severely obese subjects. Obes Surg 2008, 18: 151-4.
21. Skaaby T, Nystrup Husemoen LL, Pisinger C, et al. Vitamin D status and incident cardiovascular disease and all-cause mortality: a general population study. Endocrine 2013, 43: 618-25.
22. Kawashima H. Receptor 1,25-dihydroxyvitamin D in a vascular smooth muscle cell line derived from rat aorta. Biochem Biophys Res Commun 1987, 146: 1-6.
23. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-dihydroxyvitamin D3 is a negative endocrine regulator of the rennin-angiotensin system. J Clin Invest 2002, 110: 229-38.
24. Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007, 49: 1063-9.
25. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001, 86: 1633-7.
26. Scragg R, Khaw KT, Murphy S. Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Eur J Clin Nutr 1995, 49: 640-6.
27. Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 2009, 89: 1321-7.
28. Reid IR. Effects of calcium supplementation on circulating lipids: potential pharmacoeconomic implications. Drugs Aging 2004, 21: 7-17.
29. Zemel MB, Shi H, Greer B, Dirienzo D, Zemel PC. Regulation of adiposity by dietary calcium. FASEB J 2000, 14: 1132-8.
30. Heikkinen AM, Tuppurainen MT, Niskanen L, Komulainen M, Penttila I, Saarikoski S. Long-term vitamin D3 supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy. Eur J Endocrinol 1997, 137: 495-502.
31. Andersen R, Brot C, Mejborn H, et al. Vitamin D supplementation does not affect serum lipids and lipoproteins in Pakistani immigrants. Eur J Clin Nutr 2009, 63: 1150-3.
32. Romagnoli E, Mascia ML, Cipriani C, et al. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab 2008, 93: 3015-20.
33. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011, doi:10.1210/jc.2011-0385.